Connect with us

Technology

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board

Published

3 months ago

on

Dr Hoekema brings over four decades of successful biotech and life science leadershipDr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COONew hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships

SOUTHAMPTON, England, Oct. 2, 2024 /PRNewswire/ — Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the further strengthening of its leadership team with the appointments of Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development. The appointments continue the strong momentum at Curve following the recent appointment of Simon Jones as CFO/COO.

Dr Hoekema is a highly experienced and successful biotech executive with 40 years’ experience in the industry. He served as Chief Business Officer and member of the Executive Committee at Galapagos Pharma for 18 years, with responsibility spanning M&A, business development and IP. During his time at Galapagos, he led multiple pharma partnerships, acquisitions and divestments, including two landmark deals with Gilead. He was also part of the team that completed successful IPOs on Euronext (2005) and Nasdaq (2015). Andre serves as a member of the supervisory advisory boards of Artax Biopharma, Fibrocor Therapeutics and Mimetas BV.

Curve has also appointed Cora Griffin, an accomplished life sciences business development professional and entrepreneur, as Head of Business Development. Dr Griffin has considerable experience in developing and implementing portfolio strategies from start-ups to large pharmaceutical companies. She was previously Head of Business Development & Alliance Management at ReViral and was instrumental in the acquisition by Pfizer for US$525 million. Cora served as Anti-infectives Strategy Lead at Pfizer, responsible for the Infectious Diseases portfolio strategy for the Research Unit. She is a Jury Member for the EIC Accelerator program for the European Innovation Council and Board Observer at Oppilotech.

Simon Kerry, Chief Executive Officer of Curve Therapeutics, said: “Following the significant Series A financing, we are building a world-class leadership team to turbocharge our proprietary discovery platform and rapidly progress our pipeline. Andre’s wealth of experience in the sector and significant track record, and Cora’s visionary outlook and strategic nous, will be invaluable as we grow the business and progress our lead candidate towards the clinic. We are well placed to accelerate our ambition to build out the pipeline and work with strategic partners to address complex and challenging disease targets and improve patient outcomes.”

Andre Hoekema, PhD, new Chair of Curve Therapeutics, commented: “Curve is an ambitious and innovative biotech with the mission to revolutionize the drug discovery space with its Microcycle discovery platform. Through its pioneering and truly unique approach, Curve is building an innovative therapeutic pipeline and establishing strong relationships with major pharma. I look forward to working with Simon and the leadership team to help the Company progress to the next stage of growth.”

About Curve Therapeutics 

Curve Therapeutics is a private biotechnology company pioneering a revolutionary intracellular screening platform to enable the discovery of innovative therapeutics that address complex and challenging disease targets with the potential to transform the lives of patients. Curve originated from world-leading Microcycle research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. Curve is backed by blue chip investors including Advent Life Sciences, Epidarex Capital, Pfizer Ventures, Columbus Venture Partners and British Patient Capital. Curve has a US$1.7bn global research collaboration with MSD the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications. For more information visit: www.curvetx.com.

About Curve’s Microcycle platform

Curve has developed an IP-protected, mammalian cell platform technology, for functional screening and enrichment of diverse hexameric cyclic peptide Microcycle libraries, to identify those library members that have the desired biological activity against a therapeutic target. Curve’s platform allows direct screening for biologically active library members inside mammalian cells and facilitates small molecule hit-to-lead programs. A key advantage of the technology is that both the library and the target are present in all their native conformations within a cell. Uniquely, the compact size and rigid structure of Microcycles enables the design of non-peptide small molecule leads. The disease agnostic discovery platform can be used for a wide range of therapeutically relevant targets, including protein-protein and protein-DNA interactions, and has been used by Curve to develop a pipeline of cancer programs against targets including a dual HIF-1/HIF-2 inhibitor and an inhibitor of ATIC homodimerization.

View original content:https://www.prnewswire.co.uk/news-releases/curve-therapeutics-further-strengthens-leadership-team-with-the-appointment-of-andre-hoekema-as-new-chair-of-board-302264539.html

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MagFone Christmas & New Year Sale: Unbeatable Discounts for the Holiday Season

Published

1 hour ago

on

December 22, 2024

By

The festive season is upon us, and MagFone is here to make your holidays even brighter with an exclusive Christmas & New Year sale! From incredible discounts on best-selling products to special deals on new products, MagFone is the ultimate destination for holiday shopping. From December 18, 2024 to January 6, 2025, this sale offers up to 80% off discount for everyone. Let’s dive into the details of the most awaited sale of the year.

HONGKONG, Dec. 21, 2024 /PRNewswire-PRWeb/ — What Can You Get from MagFone Christmas & New Year Sale?

New arrival – Location Changer is only $1.99 to everyone in this MagFone Christmas & New Year Grand sales. Moreover, everyone can enjoy up to 80% OFF.

1. Best-Selling Products at Up to 70% OFF

Resolving various iOS system issues or unlocking locked Apple devices like iPhone and iPad by yourself at home with MagFone’s flagship products, now available at unbeatable prices. Best-selling products such as iPhone Unlocker, Activation Unlocker, and iOS System Recovery are up for grabs with discounts of up to 70% off. Don’t miss out on this chance to get MagFone’s best-selling products at jaw-dropping prices.

MagFone iPhone Unlocker at $20.95/month and $41.95/lifetime.MagFone Activation Unlocker at $20.95/month and $41.95/lifetime.MagFone iOS System Recovery at $17.95/month and $48.95/lifetime.

2. New Arrival to Get with Only $1.99

Whether you want to change your location on your mobile device or simulate GPS movement in various games, MagFone’s new product – Location Changer – is perfect for you. Designed for both iOS and Android users, this tool comes equipped with advanced location changing features, flexible movement speed, and customizable route. With only $1.99, it is a must-have for this Christmas sale if you have the demand to change your device location.

3. 4-in-1 Bundle to Maximize Your Savings

MagFone values all loyal customers and offers exclusive pers during the Christmas & New Year sale. A super 4-in-in bundle is at reduced prices, which enables you to get all products from MagFone with an 80% off discount. This bundle includes all the tools you need, whether you’re looking to resolve various system problems and unlocking issues or change iPhone and Android device’s location. Don’t miss this chance to get all MagFone products at unbeatable prices.

MagFone Christmas & New Year Sale is a limited-time event, running from December 18, 2024 to January 6, 2025. With discount this good, products are expected to get at the lowest price this year. Don’t wait until the last minute—start shopping now to get MagFone products at the best deals.

About MagFone:

MagFone is redefining tech innovation with state-of-the-art technology and intuitive design. Whether their flagship products like iPhone Unlocker or newly-released tools like Location Changer, MagFone products are built for performance and flexibility.

YouTube: https://www.youtube.com/@magfone

Facebook: https://www.facebook.com/magfone/

X: https://x.com/magfone

Media Contact

Olivia Wood, MagFone, 86 19186985874, support@magfone.com, https://www.magfone.com/

View original content to download multimedia:https://www.prweb.com/releases/magfone-christmas–new-year-sale-unbeatable-discounts-for-the-holiday-season-302337015.html

SOURCE MagFone

Continue Reading

Technology

Dr. Ashley Milhizer Sees 300% Growth in 2024 at Real Results Medical & Aesthetics

Published

6 hours ago

on

December 21, 2024

By

After nearly two years in business, Dr. Ashley Milhizer’s Tempe-based center for naturopathic medicine and aesthetics has experienced the type of growth that rival industry titans. Real Results Medical & Aesthetics – soon to be opening a second location in Scottsdale in early 2025 – has seen an impressive 300% growth since opening their doors in March 2023.

TEMPE, Ariz., Dec. 21, 2024 /PRNewswire-PRWeb/ — After nearly two years in business, Dr. Ashley Milhizer’s Tempe-based center for naturopathic medicine and aesthetics has experienced the type of growth that rival industry titans. Real Results Medical & Aesthetics – soon to be opening a second location in Scottsdale in early 2025 – has seen an impressive 300% growth since opening their doors in March 2023.

Aside from patient referrals and cutting-edge technology, Milhizer credits social media as one of the biggest avenues for growth. “Between TikTok and Instagram we’ve amassed over 25,000 followers and that accounts for about 70% of our new business.”

Aside from patient referrals and cutting-edge technology, Milhizer credits social media as one of the biggest avenues for growth. “Between TikTok and Instagram we’ve amassed over 25,000 followers and that accounts for about 70% of our new business,” said Dr. Ashley Milhizer, Founder of Real Results Medical & Aesthetics.

On both platforms, Dr. Milhizer shares educational videos and insights into various medical & aesthetic procedures. Her engaging content not only highlights the quality of care she provides but also educates her audience on the latest trends and treatments in the field.

Originally from Michigan, and a graduate of UC Davis and the Southwest College of Naturopathic Medicine & Health Sciences, it was Dr. Milhizer’s personal experience in seeing how natural remedies can significantly impact the body that inspired her to get into the field.

“While I was in school, a friend of mine was diagnosed with stage 3 cancer and was given up to 18 months to live and I became determined to research every kind of remedy that could potentially help,” said Dr. Milhizer. “From a healthy diet, supplements and a host of other naturopathic strategies, we tried everything we could find and two months later he was in remission, and he’s still alive today.”

The power of naturopathic remedies, following an early career path in sports medicine – which enabled her to work with some of the state’s top professional athletes – is what led her to forming Real Results Medical & Aesthetics. The company’s broad depth of services is also what allowed her to expand her reach of clientele beyond athletes to everyone from the Valley’s elite CEOs and stay at home Moms to patients ranging from their early 20s to upper 80s.

The naturopathic services offered at Real Results Medical & Aesthetics include hormone optimization, peptide therapy, IV therapy, natural pain relief, weight loss, food allergy testing and overall diagnostic testing. While the aesthetics side of the business offers services such as hair restoration, skin resurfacing, botox, fillers, microneedling, RF Plasma skin resurfacing, laser treatments, vein removal and body contouring.

For more information on Real Results Medical & Aesthetics, visit www.realresultsmedical.com or call/text 480.245.5636. For ongoing news, updates and service offerings, follow Dr. Milhizer on Facebook, Instagram and LinkedIn.

Media Contact

Kendra Riley, Real Results Medical & Aesthetics, 1 4802206051, kendra@dawningpr.com 

View original content to download multimedia:https://www.prweb.com/releases/dr-ashley-milhizer-sees-300-growth-in-2024-at-real-results-medical–aesthetics-302337009.html

SOURCE Real Results Medical & Aesthetics

Continue Reading

Technology

ICEYE expands its Earth Observation capabilities with launch of two SAR satellites for mid-inclination orbit on the Bandwagon-2 mission with SpaceX

Published

11 hours ago

on

December 21, 2024

By

Mid-inclination orbit provides more SAR-imaging opportunities at middle latitudes of the globe for ICEYE customers.

HELSINKI, Finland, Dec. 21, 2024 /PRNewswire/ — ICEYE, the global leader in SAR satellite operations for Earth Observation and persistent monitoring, announced today that it has launched two new satellites to its constellation of SAR satellites. Both satellites expand the availability of ICEYE’s latest imaging technology to deliver additional 25 cm imaging capacity. The satellites were integrated via Exolaunch and launched as part of the Bandwagon-2 rideshare mission with SpaceX from Vandenberg Space Force Base in California, USA. Both satellites have established communication, and early routine operations are underway. With today’s launch, ICEYE has successfully launched 40 satellites into orbit since 2018, with nine satellites launched in 2024 alone.

The new SAR satellites were launched into mid-inclination orbits; compared to a polar orbit, these mid-inclination orbits provide more than twice the collection opportunities at middle latitudes of the globe. ICEYE customers have many areas of interest in these middle latitudes (+/- 45 degrees), and these customers will benefit from increased persistence over these regions. Customers with imaging interests outside these middle latitudes will continue to benefit from the frequent revisit enabled by ICEYE’s dozens of satellites in polar orbits. ICEYE’s unique mix of mid-inclination and polar orbits provides its customers with deep revisit capabilities for targets all around the globe. The new satellites will serve ICEYE’s commercial missions as part of the world’s largest SAR satellite constellation owned and operated by ICEYE.

Rafal Modrzewski, CEO and Co-founder of ICEYE said: “This launch marks another significant milestone in ICEYE’s ability to provide our customers with a rich diversity of collection opportunities. We bolster our industry-leading SAR constellation and expand our customers’ collection opportunities in the areas most important to them.”

Today’s launch is another step forward in ICEYE’s steady drumbeat of innovative breakthroughs in Earth Observation. This year alone, ICEYE has, for example, introduced Dwell Precise, a new 25 cm imaging mode that offers its customers the highest-fidelity 25cm imaging capability, and adds advanced capability to ICEYE’s line of Dwell products; launched an API that allows customers to directly task its SAR satellite constellation; and launched ICEYE Ocean Vision to provide actionable intelligence for maritime domain awareness.

About ICEYE

ICEYE delivers unparalleled persistent monitoring capabilities to detect and respond to changes in any location on Earth, faster and more accurately than ever before.

Owning the world’s largest synthetic aperture radar (SAR) satellite constellation, ICEYE provides objective, near real-time insights, ensuring that customers have unmatched access to actionable high-quality data, day or night, even in challenging environmental conditions. As a trusted partner to governments and commercial industries, ICEYE delivers intelligence in sectors such as insurance, natural catastrophe response and recovery, security, maritime monitoring, and finance, enabling decision-making that contributes to community resilience and sustainable development.

ICEYE operates internationally with offices in Finland, Poland, Spain, the UK, Australia, Japan, UAE, Greece, and the US.  We have more than 700 employees, inspired by the shared vision of improving life on Earth by becoming the global source of truth in Earth Observation.

Media contact: press@iceye.com

Visit www.iceye.com and follow ICEYE on LinkedIn and X for the latest updates and insights.

View original content to download multimedia:https://www.prnewswire.com/news-releases/iceye-expands-its-earth-observation-capabilities-with-launch-of-two-sar-satellites-for-mid-inclination-orbit-on-the-bandwagon-2-mission-with-spacex-302337876.html

SOURCE ICEYE

Continue Reading

Trending